EDUCATION
- 纽约州立大学上州医科大学博士
之前的职位/预约
-
约翰霍普金斯大学研究助理
-
约翰霍普金斯大学博士后
学术/科研利益
About 70% of estrogen receptor (ER) positive breast cancers have significantly reduced the risk of invasive breast cancer by various endocrine therapies. Despite the relative safety and significant anti-neoplastic and chemopreventive activities of tamoxifen and aromatase inhibitors, many initially responsive breast tumors develop resistance and ultimately recur.
My current research is to investigate the secretome leading to the endocrine resistance in crosstalk between endocrine resistant breast cancer and tumor microenvironment.
The long-term mission of my laboratory is to understand the steps of the endocrine resistant process to develop therapeutic approaches to prevent and treat endocrine resistant breast cancer effectively. The ultimate goal of my research is to bring therapies into the clinic that will improve the survival of metastatic breast cancer patients.
课程
- 分子生物学(本科)
- 药学研究经历(本科)
- Thesis I & 二世(本科)
- Pharmacology & 癌症分子遗传学(研究生)
- 药学学报(研究生)
荣誉与成就
- NIH拨款R15 CA271221 (PI)
- NIH拨款R15 CA287244(合作者)
ACPHS委员会
- ACPHS研究委员会
- 教师参议院
- 机构生物安全委员会
- 药学硕士招生委员会
选定的出版物
Pandithar S, Galke D, Akume A, Belyakov A, Lomonaco D, Guerra AA, Park J, Reff O, Jin K. The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast. Mol Biol Rep. 2024年2月23日;51(1):331. doi: 10.1007/s11033-023-09119-4. PubMed PMID: 38393465; PubMed Central PMCID: PMC10891235.
Blakely B, Shin S， Jin K. Overview of the therapeutic strategies for ER positive breast cancer. 生物化学杂志. 2023年6月,212:115552. doi: 10.1016/j.bcp.2023.115552. Epub 2023 april 15. Review. PubMed PMID: 37068524; PubMed Central PMCID: PMC10394654.
Smrekar K, Belyakov A， Jin K. Crosstalk between triple negative breast cancer and microenvironment. Oncotarget. [2023] 3月31日;14:28 -293. doi: 10.18632 / oncotarget.28397. Review. PubMed PMID: 36999995; PubMed Central PMCID: PMC10064880.
Malone MK, Smrekar K, Park S, Blakely B, Walter A, Nasta N, Park J, Considine M, Danilova LV, Pandey NB, Fertig EJ, Popel AS, Jin K. Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy. 癌症生物学. 2020年6月2日;21(6):560-569. doi: 10.1080/15384047.2020.1739484. Epub 2020年3月26日. PubMed PMID: 32213106; PubMed Central PMCID: PMC7515526.
Jin K， Pandey NB, Popel AS. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. 乳腺癌研究进展，2018;20(1):54. (通讯作者).
Norton KA, Jin K, Popel AS. Modeling triple-negative breast cancer heterogeneity: Effects of stromal macrophages, 成纤维细胞和肿瘤血管. 理论生物学杂志2018年9月7日;452:56-68.
john D, Torga G, Ewing CM， Jin K， Norris JD, McDonnell DP, Isaacs WB. HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer. 前列腺杂志2018年12月17日. doi: 10.1002/pros.23747. [印前Epub].
Malone MS, Smrekar K, Dnilova L, Considine M, Fertig E, Park S, Blakely B, Walter A, Nasta N, Park J, Jin K, Popel A. Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy: experimental and bioinformatics predictions. 分子癌症研究2018. (通讯作者，审稿中).
Northon KA, Jin K和Popel AS. Modeling triple-negative breast cancer heterogeneity: effects of stromal macrophages, 成纤维细胞和肿瘤血管. J Theor Biol. 2018年9月7日;42:56 -68.
Jin K， Pandey NB和Popel AS. Synergistic effect of combinatorial treatment with Maraviroc and Tocilizumab on TNBC tumor growth and metastasis in mouse xenograft model. 乳腺癌研究. 2018年6月14日;20(1):54. (通讯作者)
Jin K， Pandey NB和Popel AS. Crosstalk between TNBC and stromal components via secreted factors enhances cell motility that can be attenuated by a CXCR inhibitor. Oncotarget. 2017年7月21日;8(36):60210-6022. (通讯作者)
美利奴VF，赵s，梁x，朴s， Jin K，陈强，潘东，李建军，李建军，李建军. STAT3抑制剂, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors. Mol Oncol. 2017年5月,11 (5):552 - 566.
Errico MC, Jin K， Carè A, Sukumar S. HOXB7在实体肿瘤中影响范围的扩大. Cancer Res. 2016 05月15日;76(10):2857-62.
Yoshida K*, Jin K*, Hong S, Park S, Huso D, Zhang Z, Liangfeng H, Zhu C, Bruchertseifer F, Morgenstern一, Sgouros G, Sukumar S. Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. Oncotarget. 2016 Apr 23. (*同样贡献).
Jin K 和Sukumar S. HOX genes: Major actors in resistance to selective endocrine response modifiers. 2016. BBA-Cancer审查. 1865(2):105-110.
阮KN，美利奴V， Jin K, Hillocks Y, Zhang Z, Sadik H, Korangath P, Han L, Ordentlich P, Connolly R, Stearns V, Brodie A和Sukumar S. Reactivation of silenced retinoic acid receptor-beta and potentiation of chemotherapy with Entinostat in breast cancer - preclinical validation and molecular mechanism. 2016. Cancer Res. 2016年4月1日;76(7):2013-24.
Jin K 和Sukumar S. A pivotal role for HOXB7 protein in endocrine resistant breast cancer. 2015. Oncoscience. 15;2(11):917-9.
Jin K, Park S, Teo W, Korangath P, Cho S, Yoshida T, Györffy B, Goswami C, Nakshatri H, Cruz L, Zhou W, Ji H, Su Y, Ekram M, Polyak K, 和Sukumar S. HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. 2015年，癌症发现. 9月,5 (9):944 - 59.
Liu S, Jin K, Fu J, Jie C, Zhang H, Feng S, Reissman D, Wang Q, Sukumar S, and Chen H. HOXB7 promotes tumor progression via activation of the transformation growth factor-β signaling pathway. 2015年，癌症研究. 15;75(4):709-19.
李E, Fertigc EJ， Jin K， Sukumar S, Pandey NB和Popel AS. Breast cancer cells educate lymphatic endothelial cells within pre-metastatic niches to promote metastasis. 2014，自然通讯，2;5:47 - 15.
Shah N*, Jin K*, Cruz LA, Park S, Sadik H, Cho S, Goswami CP, Nakshatri H, Gupta R, Chang HY, Zhang Z, Cimino-Mathews一, Cope L, Umbricht C和Sukumar S. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression. 2013年，癌症研究所. 73(17):5449-58. (*同样贡献)
吴晓东，吴晓东，吴晓东，吴晓东。 Jin K，韩磊，陈华，权EM，郭军，哈合和，Sukumar S. ADP ribosylation by PARP-1 suppresses HOXB7 transcriptional activity. 2012, PLoS One. 7(7):e40644.
Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi一, Landberg G, Bieche I, Wu X, Lobie PE, Davidson NE, Bhujwalla ZM评选, 朱婷和Sukumar S. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. 2012，美国国家科学基金委. 21:109(8):2736-41.
Jin K 和Sukumar S. BRCA1:将HOX与乳腺癌抑制联系起来. 2010，乳腺癌研究中心. 12(4):306.
Jin K 和Sukumar S. 他莫昔芬耐药性的克隆选择. 2010，《全球十大赌博靠谱的平台》. 9(9):717-24.
Jin K，胡俊，李建平，李建平. Mirk调节结肠癌细胞从静止状态中退出. 2009，生物化学学报. 284(34):22916-25.
Jin K， Park S, Ewton DZ, Friedman E. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer. 2007年，癌症中心. 67(15):7247-55.
Jin K， Lim S, Mercer SE和Friedman E. The survival kinase Mirk/dyrk1B is activated through Rac1-MKK3 signaling. 2005，生物化学学报. 280(51):42097-105.
Jee B, Jin K，韩建辉，宋洪柱，李辉. Metastasis-suppressor KAI1/CD82 induces homotypic aggregation of human prostate cancer cells through Src-dependent pathway. 2003，医学医学杂志. 35(1):30-7.
Kim GY, Mercer SE, Ewton DZ, Yan Z， Jin K 弗里德曼·E. The stressactivated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. 2002，生物化学学报. 277(33):29792-802.
Lim S, Jin K 弗里德曼·E. Mirk protein kinase is activated by MKK3 and functions as a transcriptional activator of HNF1alpha. 2002，生物化学学报. 277(28):25040-6.
会议和演讲
Jin K, The HOXB7 protein promotes breast cancer cell growth through activation of the CCL5/CCR5 pathway in the crosstalk of adipocyte, April 5-10, Sandiego, CA 2024.
Jin K, The role of CXCL1 in crosstalk between breast cancer cells with ESR1 mutations and lymphatic endothelial cells, April 14-19, Orlando, FL, 2023.
Jin K, Reparixin, CXCR1/2 inhibitor in combination with CDK4/6 inhibitors attenuates endocrine resistant breast cancer growth and metastasis, April 8-13, New Orleans, LA, 2022(特邀演讲)
Jin K, HOXB7, a key transcriptional regulator in triple negative breast cancer progression, 虚拟会议, April 10-15, 2021
Jin K. Crosstalk between Stromal Components and Endocrine Resistant Breast Cancer via Secreted Factors Enhances Tumor Growth and Metastasis. AACR年会，芝加哥，2018年4月14-18日.
Jin K. Crosstalk between Stromal Components and Endocrine Resistant Breast Cancer via Secreted Factors Enhances Tumor Growth and Metastasis. 纽约州立大学奥尔巴尼分校CRC研究研讨会(特邀演讲).
Jin K. Crosstalk between Stromal Components and Endocrine Resistant Breast Cancer via Secreted Factors Enhances Tumor Growth and Metastasis. 第八届年度研究论坛, 奥尔巴尼药学与健康科学学院, Albany NY, January 27, 2018(特邀演讲).
荣誉、奖励和任命
临床前催化剂项目审稿人，Breast Cancer Now (UK)
专业组织会员资格
Active Member of the American Association for Cancer Research (AACR)